Anzeige
Mehr »
Login
Mittwoch, 28.10.2020 Börsentäglich über 12.000 News von 649 internationalen Medien
Unglaublicher News-Flow!!! Diese Firma liefert einfach gewaltig ab!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von Endpoints News

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
16:35A small buyout deal gives a penny-stock biotech a boost and a second chance
16:35News briefing: SpringWorks, Jazz exchange $35M and PTSD drug; Dr. Reddy's says cyberattack was ransomware
15:35Former Allergan program posts positive topline PhIII results in farsightedness in an R&D win post-AbbVie merger
15:35Bristol Myers' Richard Hargreaves pays $70M to launch a neurodegeneration alliance with a star player in the machine learning world
15:35RemeGen readies $514M IPO as HKEX adds jewel to the crown
14:35Arena's Amit Munshi spins out his neuro sub into a biotech startup, with $56M for the baptism
13:35Chinese rare disease player inks first deal around narcolepsy drug Wakix after grabbing $80M to build an ecosystem
12:35Eli Lilly lines up a blockbuster deal for Covid-19 antibody, right after it failed a NIAID trial
12:35Enhertu picks up another win for AstraZeneca and Daiichi Sankyo, joining the priority review lane for gastric cancer
12:35Scientists warn Americans are expecting too much from a coronavirus vaccine
10:35Covid-19 roundup: Sanofi and GSK pledge 200M vaccine doses for a global distribution campaign
10:35Novartis CEO Vas Narasimhan signs off on a $231M deal to try something new in the R&D fight against SARS-CoV-2
DiA dark horse entrant into the spinal muscular atrophy field doubles its value on some PhII data
DiNews briefing: Novartis' Zolgensma hits blockbuster status, triggering $80M milestone; Caris raises $310M for genomic profiling expansion
DiSobi bets $250M cash, about $1B in milestones for rights to a C3 therapy being pushed through 5 pivotal trials
DiA month after Illumina's big Grail buyout, Exact Sciences scoops up liquid biopsy rival Thrive for a relative bargain
DiBayer follows R&D deal spree by raiding Roche's cancer group for its new research chief
DiAfter falling behind the leaders, dissed by some experts, biotech showman Patrick Soon-Shiong finally gets his Covid-19 vaccine ready for a trial. But can it live up to the hype?
DiWhere's the Pfizer efficacy readout? Pharma giant says no interim analysis done yet on Covid-19 vaccine
DiThe disruptors at EQRx have their eyes on the PD-(L)1 market - teeing up $150M cash to grab 2 backbone therapies from China
DiPatrick Soon-Shiong steps down as CEO of NantKwest, a linchpin of his 'Cancer Moonshot'
DiCovid-19 roundup: Medicare and Medicaid recipients could receive vaccines for free - report
DiResearchers shutter Eli Lilly Covid-19 study after monitors flag their antibody as a flop for hospitalized patients - but EUA hunt continues
MoThree years into a PhIII program for a failed Duchenne MD drug, Catabasis hauls down the flag and admits defeat
MoUltragenyx slams the brakes on rare disease study after all 5 patients are hit with a serious setback